Table 1.
Summary of reported COVID-19 associated mucormycosis from different geographic areas.
| Geographic areas | Case no. | Age (yr) | Gender | Underlying condition | Lesion | Mortality | Author |
|---|---|---|---|---|---|---|---|
| United Kingdom | 1 | 1 (100%) | |||||
| London | 1 | 22 | M | Obesity, hypothyroidism | Disseminated | Yes | Hanley et al.23 |
| South America | 2 | 2 (100%) | |||||
| São Paulo, Brazil | 1 | 86 | M | Corticosteroid use | Stomach | Yes | Monte Junior et al.24 |
| Mexico City, Mexico | 1 | 24 | F | Obesity | Rhino-orbital | Yes | Waizel-Haiat et al.35 |
| United States | 9 | 7 (78%) | |||||
| New York | 1 | 68 | M | Heart transplant, DM | Cutaneous | Yes | Khatri et al.16 |
| New York | 1 | 33 | F | DM | Rhino-orbital-cerebral | Yes | Werthman-Ehrenreich et al.34 |
| San Francisco, California | 1 | 60 | M | DM | Rhino-orbital | Yes | Mekonnen et al.17 |
| Riverside, California | 1 | 79 | M | Corticosteroid use | Pulmonary | no | Johnson et al.73 |
| San Diego, California | 2 | NA | NA | DM (2), corticosteroid use (2) | Rhino-orbital-cerebral (2) | 2/2 | Dallalzadeh et al.69 |
| Dover, Delaware | 1 | 41 | M | DM | Rhino-cerebral | no | Alekseyev et al.36 |
| Lewes, Delaware | 1 | 56 | M | ESRD, corticosteroid use | Lung | Yes | Kanwar et al.68 |
| Yuma, Arizona | 1 | 49 | M | Corticosteroid use | Lung | Yes | Placik et al.25 |
| European Union | 9 | 6 (67%) | |||||
| Multisite, the Netherlands | 4 | 50–70 | M (4) | DM (2), corticosteroid use (1), obesity (1) | Lung (3), orbital (1) | 3/4 | Buil et al.11 |
| Barcelona, Spain | 2 | 62, 48 | M (2) | Kidney transplant (2), DM (1), corticosteroid use (2) | Rhinosinusal (1), Musculoskeletal (1) | 0/2 | Arana et al.31 |
| Besançon, France | 1 | 55 | M | Lymphoma | Lung | Yes | Bellanger et al.72 |
| Sassari, Italy | 1 | 66 | M | Hypertension | Lung | Yes | Pasero et al.27 |
| Graz, Austria | 1 | 53 | M | Acute myeloid leukemia | Lung | Yes | Zurl et al.33 |
| Egypt | 7 | 3 (42.8%) | |||||
| Cairo | 7 | 41–67 | M (4) | DM (6) | Rhino-orbital-cerebral (7) | 3/7 | Ashour et al.29 |
| F (3) | |||||||
| Middle East | 29 | 15 (52%) | |||||
| Tehran, Iran | 1 | 61 | M | Corticosteroid use | Rhino-orbito-cerebral | no | Karimi-Galougahi et al.15 |
| Tehran, Iran | 2 | 40, 54 | M (1) | Corticosteroid use (2) | Rhino-orbital (1), rhino-orbital-cerebral (1) | 1/2 | Veisi et al.32 |
| F (1) | |||||||
| Tehran, Iran | 15 | 14–71 | M (9) | DM (13), corticosteroid use (7) | Rhino-orbital (15) | 7/15 | Pakdel et al.12 |
| F (6) | |||||||
| Kayseri, Turkey | 11 | 61–88 | M (9) | DM (8), corticosteroid use (11) | Sino-orbital (11) | 7/11 | Bayram et al.30 |
| F (2) | |||||||
| India | 3129 | 412/3106 (13%) | |||||
| Chandigarh | 1 | 55 | M | DM, ESRD, corticosteroid use | Lung | no | Garg et al.40 |
| Mangalore, Karnataka | 1 | 32 | F | DM | Rhino-orbital-cerebral | no | Saldanha et al.45 |
| Mangalore, Karnataka | 1 | NA | F | DM | Rhino-orbital-cerebral | no | Revannavar et al.43 |
| Mysuru, Karnataka | 2 | 34, 50 | M (2) | Nil | Rhino-orbital (2) | 0/2 | Sai Krishna et al.44 |
| Bangalore, Karnataka | 1 | 66 | M | DM, corticosteroid use | Rhino-orbital | no | Rao et al.42 |
| Bangalore, Karnataka | 17 | 35–73 | M (14) | DM (16), corticosteroid use (16) | Rhino-orbito-cerebral (17) | 6/17 | Moorthy et al.41 |
| F (3) | |||||||
| Puducherry | 10 | 23–67 | M (8) | DM (5), corticosteroid use (10) | Orbital (10) | 4/10 | Sarkar et al.46 |
| F (2) | |||||||
| Ahmedabad, Gujarat | 1 | 42 | M | DM, corticosteroid use | Rhino-orbital | no | Selarka et al.14 |
| Ahmedabad, Gujarat | 2 | 25, 47 | M (2) | Kidney transplant (2), DM (2) | Rhino-orbital (1), lung (1) | 2/2 | Meshram et al.47 |
| Ahmedabad, Gujarat | 19 | NA | NA | DM (19), corticosteroid use (19) | Rhino-orbital (19) | 3/19 | Ravani et al.49 |
| Bikaner, Rajasthan | 5 | 52–70 | M (1) | DM (5) | Rhino-orbital (5) | 2/5 | Nehara et al.48 |
| F (4) | |||||||
| Jaipur, Rajasthan | 23 | NA | NA | NA | Rhino-orbital-cerebral (23) | NA | Sharma et al.50 |
| Hyderabad, Telangana; Mumbai, Maharashtra | 6 | 46–74 | M (6) | DM (6), corticosteroid use (5) | Rhino-orbital (6) | 0/6 | Sen et al.53 |
| Mumbai, Maharashtra | 1 | 60 | M | DM | Rhino-orbital | Yes | Mehta et al.26 |
| Mumbai, Maharashtra | 1 | 38 | M | Corticosteroid use | Rhino-orbital-cerebral | no | Maini et al.52 |
| Mumbai, Maharashtra | 25 | NA | NA | DM (22), HIV (2), corticosteroid use (25) | Rhino-orbital-cerebral (25) | 14/25 | Joshi et al.51 |
| Multicenter | 187 | 57a | M (150) | DM (113), corticosteroid use (146), kidney transplant (3) | Rhino-orbital (117), rhino-orbital-cerebral (44), lung (16), kidney (1), disseminated (4), others (5) | 75/170 | Patel et al.13 |
| F (37) | |||||||
| 102 centers | 2826 | 12–88 | M (1993) | DM (2194), hypertension (690), renal failure (88) | Rhino-orbital-cerebral (2826) | 305/2218 | Sen et al.38 |
| F (833) |
Note. M: man; F: female; DM, diabetes mellitus; ESRD, end stage renal disease; HIV, human immunodeficiency virus; NA, not applicable.
a
Mean ± SD, 56.9 ± 12.5.